Oncology 2020: a drug development and approval paradigm

被引：21
|
作者：
Dhingra, K. [1 ]
机构：
[1] KAPital Consulting LLC, Sparta, NJ 07871 USA
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷 / 11期
关键词：
D O I：
10.1093/annonc/mdv353
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2347 / 2350
页数：4
相关论文
共 50 条
  • [1] Accelerated Approval and Oncology Drug Development Timelines
    Lanthier, Michael L.
    Sridhara, Rajeshwari
    Johnson, John R.
    Farrell, Ann
    Keegan, Patricia
    Justice, Robert
    Pazdur, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (14) : E226 - E227
  • [2] Accelerated Approval and Oncology Drug Development Timelines Reply
    Bennett, Charles L.
    Nebeker, Jonathan R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (14) : E228 - E228
  • [3] Drug development in oncology and devices—lessons for heart failure drug development and approval? a review
    Beth A. Davison
    Gad Cotter
    Gerasimos S. Filippatos
    Faiez Zannad
    Adriaan A. Voors
    Marco Metra
    John R. Teerlink
    Stefanie Senger
    Alexandre Mebazaa
    Barry Greenberg
    Heart Failure Reviews, 2021, 26 : 255 - 262
  • [4] A paradigm shift in biomarker guided oncology drug development
    Jorgensen, Jan Trost
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (07)
  • [5] Drug development in oncology and devices-lessons for heart failure drug development and approval? a review
    Davison, Beth A.
    Cotter, Gad
    Filippatos, Gerasimos S.
    Zannad, Faiez
    Voors, Adriaan A.
    Metra, Marco
    Teerlink, John R.
    Senger, Stefanie
    Mebazaa, Alexandre
    Greenberg, Barry
    HEART FAILURE REVIEWS, 2021, 26 (02) : 255 - 262
  • [6] Japanese contributions to oncology drug development and regulatory approval around the world
    Fujiwara, Yasuhiro
    Nonaka, Takahiro
    CANCER SCIENCE, 2021, 112 : 954 - 954
  • [7] Accelerated Approval and Breakthrough Therapy Designation: Oncology Drug Development on Speed?
    Yao, James C.
    Meric-Bernstam, Funda
    Lee, J. Jack
    Eckhardt, S. Gail
    CLINICAL CANCER RESEARCH, 2013, 19 (16) : 4305 - 4308
  • [8] Oncology Drug Development and Approval of Systemic Anticancer Therapy by the US Food and Drug Administration
    Martell, Robert E.
    Sermer, David
    Getz, Kenneth
    Kaitin, Kenneth I.
    ONCOLOGIST, 2013, 18 (01): : 104 - 111
  • [9] Clinical pharmacology strategies in supporting drug development and approval of antibody–drug conjugates in oncology
    Stephanie N. Liu
    Chunze Li
    Cancer Chemotherapy and Pharmacology, 2021, 87 : 743 - 765
  • [10] Immuno-Oncology: The Third Paradigm in Early Drug Development
    Juan Martin-Liberal
    Cinta Hierro
    Maria Ochoa de Olza
    Jordi Rodon
    Targeted Oncology, 2017, 12 : 125 - 138
12345